Lisa Anson

Outlook DigitalOcean Hotjar Nginx Google Font API Google Tag Manager WordPress.org Google Analytics Gravity Forms Vimeo Mobile Friendly

oncology fibrosis pharmaceuticals drug discovery & development biotech pharmaceutical manufacturing biotechnology drug discovery clinical development fibrotic diseases cancer therapies rock inhibitors zelasudil rxc008 gi-targeted pan-rock fibrostenotic crohns disease preclinical models translational science drug candidates clinical trials cancer-associated fibrosis preclinical data phase 1 study phase 2 data surgical treatment anti-fibrotic therapies inflammatory bowel disease foxfire trials biologics small molecule therapies underlying mechanisms therapeutic efficacy medicinal chemistry mechanism of action pharmacokinetics safety profiles cyp450 interactions therapeutic targets clinical endpoints secondary complications disease progression patient populations longitudinal studies cancer biology immune-mediated lung disease collaborative research key opinion leaders expert advisors biomarkers proof of concept enrollment criteria investigator-initiated studies future directions patient derived xenografts clinical-stage targeted therapies small molecules cancer treatment idiopathic pulmonary fibrosis rock2 inhibitor innovative medicines healthcare professionals patient outcomes unmet medical needs collaborations partnerships gastrointestinal diseases crohn's disease wnt-ligand dependent tumors strategic deals first-in-class best-in-class drug development healthcare innovation market engagement investor relations precision medicine therapeutic areas customer service patient-centric research & development competitive landscape emerging biotechs pharmaceutical industry hospital & health care medical health care health wellness & fitness